Psoriasis News and Research

Latest Psoriasis News and Research

Can-Fite BioPharma reports financial results, provides updates on drug development programs

Can-Fite BioPharma reports financial results, provides updates on drug development programs

Researchers begin landmark clinical study to restore normal insulin secretion in people with type 1 diabetes

Researchers begin landmark clinical study to restore normal insulin secretion in people with type 1 diabetes

Novartis announces EC approval of Cosentyx for treatment of ankylosing spondylitis, psoriatic arthritis

Novartis announces EC approval of Cosentyx for treatment of ankylosing spondylitis, psoriatic arthritis

First patient enrolled in Phase 2 clinical trial of Immune's bertilimumab in Ulcerative Colitis

First patient enrolled in Phase 2 clinical trial of Immune's bertilimumab in Ulcerative Colitis

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

CHMP recommends approval of Cosentyx in Europe to treat patients with AS and PsA, says Novartis

CHMP recommends approval of Cosentyx in Europe to treat patients with AS and PsA, says Novartis

Inhibiting JAK family of enzymes promotes rapid hair growth, new study finds

Inhibiting JAK family of enzymes promotes rapid hair growth, new study finds

LEO Pharma's Enstilar gets FDA approval for topical treatment of plaque psoriasis

LEO Pharma's Enstilar gets FDA approval for topical treatment of plaque psoriasis

Phase III trial data shows Novartis’ Cosentyx maintains clear skin, sustained efficacy in psoriasis patients

Phase III trial data shows Novartis’ Cosentyx maintains clear skin, sustained efficacy in psoriasis patients

Can-Fite's CF102 granted Orphan Drug Designation by EMA for treatment of hepatocellular carcinoma

Can-Fite's CF102 granted Orphan Drug Designation by EMA for treatment of hepatocellular carcinoma

Scientists calculate precise measurements of heritability in nine pediatric-onset autoimmune diseases

Scientists calculate precise measurements of heritability in nine pediatric-onset autoimmune diseases

Phase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumab

Phase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumab

Immune submits Bertilimumab IND application to FDA for treatment of Bullous Pemphigoid

Immune submits Bertilimumab IND application to FDA for treatment of Bullous Pemphigoid

FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept

FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept

Brodalumab therapy achieves 100% reduction in psoriasis symptoms

Brodalumab therapy achieves 100% reduction in psoriasis symptoms

Stoptober campaign focuses on skin disease research

Stoptober campaign focuses on skin disease research

Immune Pharmaceuticals’ CEO establishes stock trading plan

Immune Pharmaceuticals’ CEO establishes stock trading plan

Can-Fite BioPharma announces Q2 financial results for 2015, updates drug development programs

Can-Fite BioPharma announces Q2 financial results for 2015, updates drug development programs

Janus collaborates with Roche to develop TLR inhibitor to address several autoimmune diseases

Janus collaborates with Roche to develop TLR inhibitor to address several autoimmune diseases

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.